
GnRHa治疗中枢性性早熟女童对终身高的影响
Impact of gonadotropin-releasing hormone analogs treatment on final height in girls with central precocious puberty
目的:观察促性腺激素释放激素类似物(GnRHa)对治疗中枢性性早熟(central precocious puberty,CPP)女童终身高的作用及相关因素。方法:对26例CPP女童应用GnRHa治疗前后预测身高、骨龄的标准差分值[HtSDS(BA)]、终身高、体重指数(BMI)、初潮情况等进行评价,分析它们与终身高的相关性。结果:治疗前预测身高为151.5±5.7 cm;停药时预测身高为158.4±5.2 cm;终身高为158.0±4.0 cm,高于靶身高155.3±4.4 cm (P<0.01)。终身高与初始身高、预测身高、HtSDS(BA)正相关。治疗前BMI为17.1±2.1、治疗后BMI为19.9±3.2,两者呈正相关。停药后平均13.2±6.1个月后初潮,平均初潮年龄为12.2±0.7岁。结论:GnRHa治疗CPP可有效地改善终身高,终身高与治疗前身高及预测身高等密切相关,停药后患儿青春发育与正常儿童相似。[中国当代儿科杂志,2009,11(5):374-376]
OBJECTIVE: To study the effects of treatment with gonadotropin-releasing hormone analogs (GnRHa) on final height, weight and pubertal development in girls with central precocious puberty. METHODS: Twenty-six girls with central precocious puberty were treated with GnRHa for an average of 19.2±8.4 months. Pretreatment and posttreatment predicted adult heights (PAH) were evaluated based on the Bayley-Pineau table. The patients' heights and weights were measured monthly. Bone age (BA) was evaluated using Greulich-Plyle. Height standard deviation score for BA [HtSDS (BA)] was measured. After discontinuation of treatment, the patients were followed-up for the observation of height, weight, BA and menstruation. RESULTS: Final height averaged 158.0±4.0 cm in the 26 girls, which was greater than their target height (155.3±4.4 cm; P<0.01) and consistent with their posttreatment PAH (158.4±5.2 cm). The final height was positively corrrelated with initial height, PAH and HtSDS(BA). There was a positive correlation in the body mass index before and after treatment (r=0.724, P<0.01). Menarche occurred 13.2±6.1 months after discontinuation of treatment, with a mean menarche age of 12.2±0.7 years. CONCLUSIONS: GnRHa may increase final height in girls with central precocious puberty. Their final heights may be correlated with their initial heights and PAH. The pubertal development after GnRHa treatment in girls with central precocious puberty may be matched with normal children.[Chin J Contemp Pediatr, 2009, 11 (5):374-376]
促性腺激素释放激素类似物 / 性早熟 / 预测身高 / 终身高 / 女童
Gonadotropin-releasing hormone analogs / Precocious puberty / Predicted height / Final height / Girl
[1]Bridges NA, Christopher JA, Hindmarsh PC, Brook CG. Sexual precocity: sex incidence and aetiology[J].Arch Dis Child, 1994, 70(2):116-118.
[2]中华医学会儿科学分会内分泌遗传代谢学组.中枢性(真性)性早熟诊治指南[J].中华儿科杂志, 2007, 6(6):462-467.
[3]Pasquino AM, Pucarelli I, Roggini M, Segni M. Adult height in short normal girls treated with gonadotropin-releasing hormone analogs and growth hormone[J]. J Clin Endocrinol Metab, 2000, 85(2):619-622.
[4]杜敏联,马华梅,陈雪琼.促性腺素释放激素类似物对特发性中枢性性早熟女孩生长的影响[J].中华内分泌代谢杂志, 2000, 5(5):277-280.
[5]Klein KO, Barnes KM, Jones JV, Feuillan PP, Cutler GB Jr. Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience[J]. J Clin Endocrinol Metab, 2001, 86(10):4711-4716.
[6]Pasquino AM, Pucarelli I, Accardo F, Demiraj V, Segni M, Di Nardo R. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function[J]. J Clin Endocrinol Metab, 2008, 93(1):190-195.
[7]倪继红,王伟,翟淑萍,杜晓飞,王德芬. 促性腺激素释放激素类似物治疗特发性中枢性性早熟促身高增长疗效观察[J].中华内分泌代谢杂志, 2006, 8(4):365-366.
[8]Viru A. Plasma hormones and physical exercise[J]. Int J Sports Med, 1992, 13(3):201-209.
[9]Martín Díaz MJ, Soriano Guillén L, Muoz Calvo MT, Pozo Román J, Argente Oliver J.Triptorelin therapy in girls with central precocious puberty increases body mass index[J]. An Pediatr (Barc), 2006, 11,65(5):428-433.
[10]Palmert MR, Mansfield MJ, Crowley WF Jr, Crigler JF Jr, Crawford JD, Boepple PA. Is obesity an outcome of gonadotropin-releasing hormone agonist administration? Analysis of growth and body composition in 110 patients with central precocious puberty[J]. J Clin Endocrinol Metab, 1999, 84(12):4480-4488.
[11]Arrigo T, De Luca F, Antoniazzi F, Galluzzi F, Segni M, Rosano M, et al. Reduction of baseline body mass index under gonadotropinsuppressive therapy in girls with idiopathic precocious puberty[J]. Eur J Endocrinol, 2004, 150(4):533-537.
[12]Cole TJ, Bellizzi MC, Flegal KM, Dietz WH. Establishing a standard definition for child overweight and obesity worldwide: international survey[J]. BMJ, 2000, 320(7244):1240-1243.
[13]陈少科,郭先鸣.醋酸亮丙瑞林缓释剂对中枢性性早熟女童生长和成年终身高预测的影响[J].中国当代儿科杂志,2002,4(6):506-508.